Expression of CK-19, cErbB2, galectin-3, and p53 in papillary thyroid carcinomas;Papiller tiroid karsinomlarında CK-19, cErb B2, galectin-3 ve p53 ekspresyonu

Turkish Journal of Medical Sciences

Volumn 40, Issue 2, 2010, Pages 207-212

  Seckin, Selda ^a   Karagece, Ülker ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

CErbB2; CK 19; Galectin 3; p53; Papillary thyroid carcinoma; Papillary thyroid microcarcinoma

Indexed keywords

CELL PROLIFERATION;

CERBB2; CK-19; GALECTIN-3; PAPILLARY THYROID CARCINOMATA; PAPILLARY THYROID MICROCARCINOMA;

MICROCOMPUTERS;

CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GALECTIN 3; PROTEIN P53;

ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR VOLUME;

EID: 77952484034     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0808-26     Document Type: Article

References (14)

1. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001; 14(4): 338-342.
2. Khurana KK, Truong LD, LiVolsi VA, Baloch ZW. Cytokeratin-19 immunolocalization in cell block preparation of thyroid aspirates. An adjunct to fine-needle aspiration diagnosis of papillary thyroid carcinoma. Arch Pathol Lab Med 2003; 127(5): 579-583.
3. Nasir MR, Mukhopadhyay S, Zhang S, Katzenstein AL. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HMBE-1 combined with CK-19 immunostaining. Mod Pathol 2006; 19(12): 1631-1637.
4. Utrilla JC, Lacave IM, San Martin MV, Fernandez-Santos JM, Davidson GH. Expression of c- erbB2 oncoprotein in human thyroid tumours. Histopathology 1999; 34: 60-65.
5. Ensinger C, Prommegger R, Kendler D, Gabriel M, Spizzo G. Her2/ neu expression in poorly- differentiated and anaplastic thyroid carcinomas. Anticancer Research 2003; 23: 2349-2354.
6. Prasad ML, Pellegata NS, Huang Y, Nagaraja HN, Chapelle A. Galectin-3, fibronectin-1, CITED-1, HMBE-1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol 2005; 18: 48-57.
7. de Matos PS, Ferreira AP, de Oliveiria Facuri F, Assumpcao LV, Metze K, Ward LS. Usefulness of HMBE-1, cytokeratin-19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology 2005; 47(4): 391-401.
8. Zafon C, Obilos G, Castellvi J, Tallada N, Baena JA. Clinical significance of RET/PTC and p53 protein expression in sporadic papillary thyroid carcinoma. Histopathology 2007; 50: 225-231.
9. Lemoine NR, Wyllie FS, Lillehaug JR, Staddon SL, Hughes CM, Aasland R, Shaw J, Varhaug JE, Brown CL and Gullic WJ. Absence of abnormalities of the cErbB1 and cErbB2 protooncogenes in human thyroid neoplasia. Eur J Cancer 1990; 26: 777-779.
10. Sugg SL, Ezzat S, Zeng L, Rosen IB, Freeman JR, Asa SL. Cytoplasmic staining of erbb-2 but not mRNA level correlates with differentiation in human thyroid neoplasia. Clin Endocrinol (Oxf). 1998 Nov; 49(5): 629-37.
11. Aksalen LA, Varhaug JE. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor reseptor, c-erbB-2 protein, estrogen reseptor related protein, p21-ras protein, and proliferation indicators in relations to tumor recurrences and patient survival. Cancer 1995; 76: 1643-1654.
12. Haugen DR, Akslen LA, Varhaug JE, Lillehaug JR. Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer. 1992 Jun; 65(6): 832-7.
13. Cvejic D, Savin S, Petrovic I, Paunovic I, Tatic S. Galectin-3 expression in papillary microcarcinoma of the thyroid. Histopathology 2005; 47(2): 209-214.
14. Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dorken B. BAX expression in benign and malignant thyroid tumours: dysregulation of wild-type p53 is associated with a high BAX and p21 expression in thyroid carcinoma. Int J Cancer 2001; 92: 805-811.